Adipocytokine concentrations in children with different types of beta-thalassemia

References

• Muncie HL Jr, Campbell J. Alpha and beta thalassemia. Am Fam Physician 2009;80:339–44.
   PubMed Web of Science ®Google Scholar
• Weatherall DJ. The thalassaemias. BMJ 1997;314:1675–8.
   PubMed Web of Science ®Google Scholar
• Kanavaki I, Makrythanasis P, Lazaropoulou C, Tsironi M, Kattamis A, Rombos I, Papassotiriou I. Soluble endothelial adhesion molecules and inflammation markers in patients with beta-thalassemia intermedia. Blood Cells Mol Dis 2009;43:230–4.
   PubMed Web of Science ®Google Scholar
• Kamada Y, Takehara T, Hayashi N. Adipocytokines and liver disease. J Gastroenterol 2008;43:811–22.
   PubMed Web of Science ®Google Scholar
• Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insülin. Science 2005;307:426–30.
   PubMed Web of Science ®Google Scholar
• Anfossi G, Russo I, Doronzo G, Pomero A, Trovati M. Adipocytokines in atherothrombosis: focus on platelets and vascular smooth muscle cells. Mediators Inflamm 2010; 2010:174341. doi: 10.1155/2010/174341.
   PubMed Web of Science ®Google Scholar
• Chaliasos N, Challa A, Hatzimichael E, Koutsouka F, Bourantas DK, Vlahos AP, Siamopoulou A, Bourantas KL, Makis A. Serum adipocytokine and vascular inflammation marker levels in Beta-thalassaemia major patients. Acta Haematol 2010;124:191–6.
   Google Scholar
• Chung CP, Long AG, Solus JF, Rho YH, Oeser A, Raggi P, Stein CM. Adipocytokines in systemic lupus erythematosus: relationship to inflammation, insulin resistance and coronary atherosclerosis. Lupus 2009;18:799–806.
   PubMed Web of Science ®Google Scholar
• Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. Nature 2001; 409:307–12.
   PubMed Web of Science ®Google Scholar
• Lehrke M, Reilly MP, Millington SC, Iqbal N, Rader DJ, Lazar MA. An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med 2004;2:161–8.
   Google Scholar
• Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005;174:5789–95.
   PubMed Web of Science ®Google Scholar
• Verma S, Li SH, Wang CH, Fedak PW, Li RK, Weisel RD, Mickle DA. Resistin promotes endothelial cell activation: further evidence of adipokineendothelial interaction. Circulation 2003;108:736–40.
   PubMed Web of Science ®Google Scholar
• Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 1994;14:1431–7.
   PubMed Web of Science ®Google Scholar
• Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, Tilg H. Visfatin, an adipocytokine with proinflammatory and ımmunomodulating properties. J Immunol 2007;178:1748–58.
   PubMed Web of Science ®Google Scholar
• Hartge MM, Unger T, Kintscher U. The endothelium and vascular inflammation in diabetes. Diab Vasc Dis Res 2007;4:84–8.
   PubMedGoogle Scholar
• Taher AT, Otrock ZK, Uthman I, Cappellini MD. Thalassemia and hypercoagulability. Blood Rev 2008;22:283–92.
   PubMed Web of Science ®Google Scholar
• Aggeli C, Antoniades C, Cosma C, Chrysohoou C, Tousoulis D, Ladis V, Karageorga M, Pitsavos C, Stefanadis C. Endothelial dysfunction and inflammatory process in transfusion-dependent patients with beta thalassemia major. Int J Cardiol 2005;105:80–4.
   PubMed Web of Science ®Google Scholar
• Butthep P, Bunyaratvej A, Funahara Y, Kitaguchi H, Fucharoen S, Sato S, Bhamarapravati N. Alterations in vascular endothelial cell-related plasma proteins in thalassaemic patients and their correlation with clinical symptoms. Thromb Haemost 1995;74:1045–9.
   PubMed Web of Science ®Google Scholar
• Butthep P, Rummavas S, Wisedpanichkij R, Jindadamrongwech S, Fucharoen S, Bunyaratvej A. Increased circulating activated endothelial cells, vascular endothelial growth factor, and tumor necrosis factor in thalassemia. Am J Hematol 2002;70:100–6.
   PubMed Web of Science ®Google Scholar
• Kyriakou DS, Alexandrakis MG, Kyriakou ES, Liapi D, Kourelis TV, Passam F, Papadakis A. Activated peripheral blood and endothelial cells in thalassemia patients. Ann Hematol 2001;80:577–83.
   PubMed Web of Science ®Google Scholar
• Shitrit D, Tamary H, Koren A, Levin C, Bargil-Shitrit A, Sulkes J, Kramer MR. Correlation of vascular endothelial growth factor with the severity of thalassemia intermedia. Blood Coagul Fibrinolysis 2008;19:611–4.
   PubMedGoogle Scholar
• Hovav T, Goldfarb A, Artmann G, Yedgar S, Barshtein G. Enhanced adherence of beta-thalassaemic erythrocytes to endothelial cells. Br J Haematol 1999;106:178–81.
   PubMed Web of Science ®Google Scholar
• Silswal N, Singh AK, Aruna B, Mukhopadhyay S, Ghosh S, Ehtesham NZ. Human resistin stimulates the proinflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappa betaB-dependent pathway. Biochem Biophys Res Commun 2005;334:1092–101.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Kiyohara T, Murayama Y, Kihara S, Okamoto Y, Funahashi T, Ito T, Nezu R, Tsutsui S, Miyagawa JI, Tamura S, Matsuzawa Y, Shimomura I, Shinomura Y. Production of adiponectin, an anti-inflammatory protein, in mesenteric adipose tissue in Crohn's disease. Gut 2005;54:789–96.
   PubMed Web of Science ®Google Scholar
• Yu R, Xie S, Chen J, Zhang L, Dai Y. The effects of PACAP and related peptides on leptin, soluble leptin receptor and resistin in normal condition and LPS-induced inflammation. Peptides, 2009;30:1456–9.
   Google Scholar
• Vozarova de Courten B, Degawa-Yamauchi M, Considine RV, Tataranni PA. High serum resistin is associated with an increase in adiposity but not a worsening of insulin resistance in Pima Indians. Diabetes 2004;53:1279–84.
   PubMedGoogle Scholar
• McTernan PG, Fisher FM, Valsamakis G, Chetty R, Harte A, McTernan CL, Clark PM, Smith SA, Barnett AH, Kumar S. Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. J Clin Endocrinol Metab 2003;88:6098–106.
   PubMed Web of Science ®Google Scholar
• Silha JV, Krsek M, Skrha JV, Sucharda P, Nyomba BL, Murphy LJ. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. Eur J Endocrinol 2003;149:331–5.
   PubMed Web of Science ®Google Scholar
• Szapary PO, Bloedon LT, Samaha FF, Duffy D, Wolfe ML, Soffer D, Reilly MP, Chittams J, Rader DJ. Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler Thromb Vasc Biol 2006;26:182–8.
   PubMed Web of Science ®Google Scholar
• Mazurek T, Zhang L, Zalewski A, Mannion JD, Diehl JT, Arafat H, Sarov-Blat L, O’Brien S, Keiper EA, Johnson AG, Martin J, Goldstein BJ, Shi Y. Human epicardial adipose tissue is a source of inflammatory mediators. Circulation 2003;108:2460–6.
   PubMed Web of Science ®Google Scholar
• Baker AR, Silva NF, Quinn DW, Harte AL, Pagano D, Bonser RS, Kumar S, McTernan PG. Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular disease. Cardiovasc Diabetol 2006;5:1–7.
   PubMed Web of Science ®Google Scholar
• Ognjanovic S, Bao S, Yamamoto SY, Garibau-Tupas J, Samal B, Bryant-Greenwood GD. Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes. J Mol Endocrinol 2001;26:107–17.
   PubMed Web of Science ®Google Scholar
• Kralisch S, Klein J, Lossner U, Bluher M, Paschke R, Stumvoll M, Fasshauer M. Interleukin-6 is a negative regulator of visfatin gene expression in 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab 2005;289:586–90.
   PubMed Web of Science ®Google Scholar
• Kralisch S, Klein J, Lossner U, Bluher M, Paschke R, Stumvoll M, Fasshauer M. Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes. J Endocrinol 2005;185:1–8.
   PubMed Web of Science ®Google Scholar
• Stephens JM, Vidal-Puig AJ. An update on visfatin/pre-B-cell colony enhancing factor, an ubiquitously expressed, illusive cytokine that is regulated in obesity. Curr Opin Lipidol 2006;17:128–31.
   PubMedGoogle Scholar
• Jia SH, Li Y, Parodo J, Kapus A, Fan L, Rotstein OD, Marshall JC. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 2004;113:1318–27.
   PubMed Web of Science ®Google Scholar
• Ye SQ, Simon BA, Maloney JP, Zambelli-Weiner A, Gao L, Grant A, Easley RB, McVerry BJ, Tuder RM, Standiford T, Brower RG, Barnes KC, Garcia JG. Pre-B-cell colony-enhancing factor as a potential novel biomarker in acute lung injury. Am J Respir Crit Care Med 2005;171: 361–70.
   PubMed Web of Science ®Google Scholar
• Sethi JK, Vidal-Puig A. Visfatin: the missing link between intra-abdominal obesity and diabetes?Trends Mol Med 2005;11:44–7.
   Google Scholar
• Haider DG, Holzer G, Schaller G, Weghuber D, Widhalm K, Wagner O Kapiotis S, Wolzt M. The adipokine visfatin is markedly elevated in obese children. JPGN 2006; 43:548–9.
   Google Scholar
• Tan BK, Chen J, Digby JE, Keay SD, Kennedy CR, Randeva HS. Increased visfatin messenger ribonucleic acid and protein levels in adipose tissue and adipocytes in women with polycystic ovary syndrome: parallel increase in plasma visfatin. J Clin Endocrinol Metab 2006;91:5022–8.
   PubMed Web of Science ®Google Scholar
• Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, Lee YJ. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006;91:295–9.
   PubMed Web of Science ®Google Scholar
• Lopez-Bermejo A, Chico-Julia B, Fernandez-Balsells M, Recasens Esteve E, Casamitjana R, Ricart W, Fernández-Real JM. Serum visfatin increases with progressive beta-cell deterioration. Diabetes 2006;55:2871–5.
   PubMed Web of Science ®Google Scholar
• Berndt J, Kloting N, Kralisch S, Kovacs P, Fasshauer M, Schon MR, Stumvoll M, Blüher M. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005;54:2911–6.
   PubMed Web of Science ®Google Scholar
• Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, Serra R, Milan G, Rossato M, Federspil G, Vettor R. Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 2006;91:3165–70.
   PubMed Web of Science ®Google Scholar
• Yang H, Lavu S, Sinclair DA. Nampt/PBEF/Visfatin: a regulator of mammalian health and longevity?Experim Gerontol 2006;41:718–26.
   PubMed Web of Science ®Google Scholar
• Bae SK, Kim SR, Kim JG, Kim JY, Koo TH, Jang HO, Yun I, Yoo MA, Bae MK. Hypoxic induction of human visfatin gene is directly mediated by hypoxia-inducible factor-1. FEBS Lett 2006;580:4105–13.
   PubMed Web of Science ®Google Scholar
• Segawa K, Fukuhara A, Hosogai N, Morita K, Okuno Y, Tanaka M, Nakagawa Y, Kihara S, Funahashi T, Komuro R, Matsuda M, Shimomura I. Visfatin in adipocytes is upregulated by hypoxia through HIF1alpha-dependent mechanism. Biochem Biophys Res Commun 2006;349:875–82.
   PubMed Web of Science ®Google Scholar
• Kendal CE, Bryant-Greenwood GD. Pre-B-cell colonyenhancing factor (PBEF/Visfatin) gene expression is modulated by NF-kappaB and AP-1 in human amniotic epithelial cells. Placenta 2006;28:305–14.
   Google Scholar